GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CombiGene AB (OSTO:COMBI) » Definitions » Capex-to-Operating-Cash-Flow

CombiGene AB (OSTO:COMBI) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is CombiGene AB Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

CombiGene AB's Capital Expenditure for the three months ended in Dec. 2024 was kr0.00 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2024 was kr-6.23 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


CombiGene AB Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for CombiGene AB's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CombiGene AB Capex-to-Operating-Cash-Flow Chart

CombiGene AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - 0.01 - - -

CombiGene AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CombiGene AB's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, CombiGene AB's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CombiGene AB's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CombiGene AB's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CombiGene AB's Capex-to-Operating-Cash-Flow falls into.


;
;

CombiGene AB Capex-to-Operating-Cash-Flow Calculation

CombiGene AB's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -29.949
=N/A

CombiGene AB's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -6.231
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CombiGene AB  (OSTO:COMBI) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


CombiGene AB Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of CombiGene AB's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


CombiGene AB Business Description

Industry
Traded in Other Exchanges
N/A
Address
Agavagen 52A, Lidingo, SWE, SE-181 55
CombiGene AB is a gene therapy explorer based in Sweden. The company is engaged in developing new methods for the treatment of neurological diseases and for epileptic patients who cannot be helped by available medical treatments at present. It develops gene therapies with the ambition to offer patients affected by severe life-changing diseases opportunities for a better life.

CombiGene AB Headlines

No Headlines